Hims & Hers Health Registered (A) WKN: A2QMYY ISIN: US4330001060 Forum: Aktien Thema: Hauptdiskussion

Knallts

Jetzt Knalles

Wir kratzen hautnah an der 60$ Marke

https://threadreaderapp.com/thread/1950227869256601658.html Geht das so ? Erstmal zu den Stärken Die Schwächen kommen später

Kannst du es kopieren ? Geht nicht ohne X

Neuer Anlauf!

Sieht ganz gut aus ☺️

Kleiner Deepdive von Hims-Investor Dave auf X. Leider geht unroll nicht mehr. Hoffe auch alle ohne x können es lesen. https://x.com/eventuallywlthy/status/1950227869256601658?s=46&t=MDG-QNOIqjL3Ut6oCHd6tg

Laut Peter Prinzip bekommt sie jetzt nen noch höheren Job. Gibts da was ?

Wie geht's bis zu den Zahlen weiter? Haben unsere Chart Experten Tendenzen? 🤔

https://youtu.be/u2J50hUqJdY?si=fIzhShCsdVlLLfzf Antonio - Hims

https://youtu.be/u2J50hUqJdY?si=fIzhShCsdVlLLfzf Asymmetric Investing HIMS

Das kostet die vdL den Job

Neuer CEO bei Novo Novo Nordisk (NVO) named company veteran Maziar Mike Doustdar as its new CEO after lowering its 2025 financial outlook due in part to slowed sales of its popular GLP-1 drugs Wegovy and Ozempic. "I come to this role with a sense of urgency, a laser focus on high performance, and a fierce determination for Novo Nordisk to aim higher than it’s ever done, and to deliver to many more patients the innovation they need," Doustdar said in a company statement announcing his appointment. "This is an important moment for Novo Nordisk. The market is developing rapidly, and the company needs to address recent market challenges with speed and ambition," said Novo Nordisk Chair Helge Lund in the same statement. "I believe Novo Nordisk will build on its strengths as a global leader in obesity and diabetes, and Mike has a clear vision of how to unlock the full potential of the opportunities ahead," Lund added.